226 related articles for article (PubMed ID: 10350678)
21. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
Sherrod JP; Krist A
J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
[No Abstract] [Full Text] [Related]
22. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
Mosca LJ
Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the secondary prevention of coronary heart disease.
Veverka A; Jolly JL
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):877-89. PubMed ID: 15500433
[TBL] [Abstract][Full Text] [Related]
24. Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
Gotto AM; Kuller LH
Circulation; 2002 Jan; 105(2):136-9. PubMed ID: 11790688
[No Abstract] [Full Text] [Related]
25. [Primary prevention remains expensive, notwithstanding the consensus on lowering serum cholesterol levels].
Bonneux L; Barendregt JJ
Ned Tijdschr Geneeskd; 1999 Apr; 143(15):772-5. PubMed ID: 10347637
[TBL] [Abstract][Full Text] [Related]
26. In patients with heart disease, is the benefit of lipid-lowering therapy with statins similar in older patients to that in younger patients?
Adelman A
J Fam Pract; 2001 Nov; 50(11):924. PubMed ID: 11711002
[No Abstract] [Full Text] [Related]
27. The benefit of cholesterol-lowering medications after coronary revascularization: a population study.
Brophy JM; Brassard P; Bourgault C
Am Heart J; 2005 Aug; 150(2):282-6. PubMed ID: 16086931
[TBL] [Abstract][Full Text] [Related]
28. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
[TBL] [Abstract][Full Text] [Related]
29. Critical appraisal of revised cholesterol guidelines for the very high-risk patient.
Rosenson R; Lloyd-Jones D;
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256
[TBL] [Abstract][Full Text] [Related]
30. Cholesterol-lowering and vascular reactivity in relation to coronary heart disease.
de Divitiis M; Rubba P
Nutr Metab Cardiovasc Dis; 1999 Jun; 9(3):133-42. PubMed ID: 10464786
[TBL] [Abstract][Full Text] [Related]
31. [Cholesterol-lowering therapy; a recommendation from the Health Council].
Simoons ML
Ned Tijdschr Geneeskd; 2000 Dec; 144(51):2442-4. PubMed ID: 11151651
[TBL] [Abstract][Full Text] [Related]
32. Primary prevention of CHD: nine ways to reduce risk.
Havranek EP
Am Fam Physician; 1999 Mar; 59(6):1455-63, 1466. PubMed ID: 10193589
[TBL] [Abstract][Full Text] [Related]
33. The pharmacoeconomic benefits of cholesterol reduction.
Gonzalez ER
Am J Manag Care; 1998 Feb; 4(2):223-30. PubMed ID: 10178493
[TBL] [Abstract][Full Text] [Related]
34. [The treatment of hypercholesterolemia in primary and secondary prevention].
Sirtori CR
Ann Ital Med Int; 1995 Oct; 10 Suppl():48S-52S. PubMed ID: 8562266
[TBL] [Abstract][Full Text] [Related]
35. Reassessment of the value of lowering serum cholesterol. Questioning the wisdom of widespread intervention.
Labreche DG
Clin Pharm; 1988 Aug; 7(8):592-603. PubMed ID: 3048850
[No Abstract] [Full Text] [Related]
36. High cholesterol levels in healthy seniors: cause for concern?
Drown DJ
Prog Cardiovasc Nurs; 1995; 10(1):40-1. PubMed ID: 7770441
[No Abstract] [Full Text] [Related]
37. Managing drug therapy: new insights into the National Cholesterol Education Program guidelines.
Miller NH
AAOHN J; 1994 Mar; 42(3):108-12. PubMed ID: 8147995
[TBL] [Abstract][Full Text] [Related]
38. Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?
Grundy SM
Postgrad Med; 1998 Nov; 104(5):117-20, 123-4, 129. PubMed ID: 9823389
[TBL] [Abstract][Full Text] [Related]
39. The primary preventiono of ischemic heart disease by means of Atromid-S (clofibrate).
Oliver MF
Bull N Y Acad Med; 1968 Aug; 44(8):1021-7. PubMed ID: 4875747
[No Abstract] [Full Text] [Related]
40. [The continuing debate on the treatment of hypercholesterolemia in the primary prevention of coronary disease. What did cholesterol do to deserve that?].
Ros Rahola E
Med Clin (Barc); 1997 Oct; 109(14):542-5. PubMed ID: 9508615
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
